NICE does not recommend Opdivo (nivolumab) as a treatment for squamous NSCLC- BMS
The National Institute for Health and Care Excellence (NICE) in draft guidance has not recommended Opdivo (nivolumab) from BMS as a cost effective treatment for adult patients with locally advanced squamous NSCLC whose disease has progressed after prior chemotherapy. This rejection was made despite an offer of discount by BMS. Opdivo had shown in the CHECKMATE- 017 trial that 42% of patients with advanced squamous NSCLC were still alive at one year compared to 24% of those treated with docetaxel. The guidance is now for consultation.
Related news and insights
NRx Pharmaceuticals announced the publication of peer-reviewed results from a prospective, open-label, administratively controlled trial of aviptadil for the treatment of respiratory failure in patients with Critical COVID-19.
Biogen Inc. announced topline results from its pivotal Phase III VALOR study of tofersen (BIIB 067), an investigational antisense drug being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).
UCB, announced that the FDA has informed the Company that they were unable to complete review of the Biologics License Application (BLA) for bimekizumab for the treatment of moderate to severe plaque psoriasis by the Prescription Drug User Fee Action (PDUFA) date of October 15, 2021.